Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;32(2):e2277.
doi: 10.1002/rmv.2277. Epub 2021 Jul 19.

Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies

Maryam Noori  1 , Seyed Aria Nejadghaderi  2   3 , Shahnam Arshi  4 , Kristin Carson-Chahhoud  5   6 , Khalil Ansarin  7   8 , Ali-Asghar Kolahi  4 , Saeid Safiri  8   9
Affiliations

Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies

Maryam Noori et al. Rev Med Virol. 2022 Mar.

Abstract

BNT162b2 and mRNA-1273 are two types of mRNA-based vaccine platforms that have received emergency use authorization. The emergence of novel severe acute respiratory syndrome (SARS-CoV-2) variants has raised concerns of reduced sensitivity to neutralization by their elicited antibodies. We aimed to systematically review the most recent in vitro studies evaluating the effectiveness of BNT162b2 and mRNA-1273 induced neutralizing antibodies against SARS-CoV-2 variants of concern. We searched PubMed, Scopus, and Web of Science in addition to bioRxiv and medRxiv with terms including 'SARS-CoV-2', 'BNT162b2', 'mRNA-1273', and 'neutralizing antibody' up to June 29, 2021. A modified version of the Consolidated Standards of Reporting Trials (CONSORT) checklist was used for assessing included study quality. A total 36 in vitro studies meeting the eligibility criteria were included in this systematic review. B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) are four SARS-CoV-2 variants that have recently been identified as variants of concern. Included studies implemented different methods regarding pseudovirus or live virus neutralization assays for measuring neutralization titres against utilized viruses. After two dose vaccination by BNT162b2 or mRNA-1273, the B.1.351 variant had the least sensitivity to neutralizing antibodies, while B.1.1.7 variant had the most sensitivity; that is, it was better neutralized relative to the comparator strain. P.1 and B.1.617.2 variants had an intermediate level of impaired naturalization activity of antibodies elicited by prior vaccination. Our review suggests that immune sera derived from vaccinated individuals might show reduced protection of individuals immunized with mRNA vaccines against more recent SARS-CoV-2 variants of concern.

Keywords: BNT162b2; SARS-CoV-2; mRNA-1273; neutralizing antibody; variants of concern.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

FIGURE 1
FIGURE 1
Study selection process
FIGURE 2
FIGURE 2
Percentage of modified Consolidated Standards of Reporting Trials (CONSORT) scores for included studies per item
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO Coronavirus (COVID‐19) Dashboard. https://covid19.who.int/
    1. EUA AT, Agnihothram S. Emergency Use Authorization (EUA) for an unapproved product review memorandum identifying information.
    1. WHO lists Moderna vaccine for emergency use. https://www.who.int/news/item/30‐04‐2021‐who‐lists‐moderna‐vaccine‐for‐e...
    1. Huang Y, Yang C, Xu X‐f, Xu W, Liu S‐w. Structural and functional properties of SARS‐CoV‐2 spike protein: potential antivirus drug development for COVID‐19. Acta Pharmacol Sin. 2020;41:1141‐1149. 10.1038/s41401-020-0485-4 - DOI - PMC - PubMed
    1. Du L, He Y, Zhou Y, Liu S, Zheng B‐J, Jiang S. The spike protein of SARS‐CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226‐236. - PMC - PubMed

Publication types

Supplementary concepts